Lower urinary tract function and pharmacologic management of lower urinary tract dysfunction.
Because of renewed interest in the neuropharmacology and neurophysiology of the urinary bladder and its outlet, drug therapy can now help manage many types of voiding dysfunction. This article summarizes the scientific foundations on which this type of therapy is based and the current drug usage in this area.
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004121:Dimethyl Sulfoxide / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D013566:Sympathomimetics / Q000627:therapeutic use; D014521:Urethra / Q000502:physiology; D001743:Urinary Bladder / Q000187:drug effects / Q000502:physiology; D014551:Urinary Tract / Q000187:drug effects; D014553:Urinary Tract Physiological Phenomena; D014554:Urination / Q000187:drug effects; D014563:Urodynamics; D014570:Urologic Diseases / Q000188:drug therapy / Q000503:physiopathology*
D000929:Antidepressive Agents, Tricyclic; D002121:Calcium Channel Blockers; D004967:Estrogens; D010276:Parasympatholytics; D010277:Parasympathomimetics; D011453:Prostaglandins; D013566:Sympathomimetics; D004121:Dimethyl Sulfoxide